Synthesis method of noradrenaline hydrochloride
By reacting chloroacetylcatechol with ulotropine and hydrolysis in the presence of hydrochloric acid, the problems of difficulty in operating, contamination and low yield of the norepinephrine hydrochloride synthesis method in the prior art are solved, and the problem of low operation is achieved. An efficient and safe synthesis process.
Patent Information
- Application Number
- CN202111265788.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-10-28
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2041-10-28
AI Technical Summary
The existing norepinephrine hydrochloride synthesis method has problems such as difficulty in operation, heavy pollution and low yield.
The first reaction is carried out with chloroacetylcatechol and ulotropine, and then mixed with hydrochloric acid to perform the second reaction. The norepinephrine hydrochloride is obtained by hydrolysis, using potassium iodide or sodium carbonate as the catalyst, methanol or ethanol as the solvent, Control reaction conditions to achieve efficient synthesis.
It realizes the advantages of safe and simple operation, fast reaction speed, complete raw material reaction and high product yield.
Smart Images

Figure CN116041194B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of organic synthesis, and in particular to a method for synthesizing noradrenaline hydrochloride. Background Art
[0002] Noradrenaline hydrochloride is also called noradrenaline hydrochloride, and the compound name is 4-(aminoacetyl)-1,2-catechol hydrochloride. In the prior art, chloroacetylcatechol is directly reacted with liquid ammonia to prepare noradrenaline hydrochloride, which has the problems of difficult reaction operation, heavy pollution, low yield, etc. The existing synthesis method of noradrenaline hydrochloride still needs to be improved. Summary of the invention
[0003] The present invention aims to solve one of the technical problems in the related art at least to a certain extent. To this end, one object of the present invention is to provide a method for synthesizing noradrenaline hydrochloride. The method has the advantages of safe and simple operation, fast reaction speed, complete reaction of raw materials, and high product yield.
[0004] In one aspect of the present invention, the present invention provides a method for synthesizing noradrenaline hydrochloride. According to an embodiment of the present invention, the method comprises: (1) subjecting the compound represented by formula I to a first reaction with urotropine to obtain a compound represented by formula II; (2) mixing the compound represented by formula II with hydrochloric acid and subjecting the mixture to a second reaction to obtain noradrenaline hydrochloride represented by formula III;
[0005]
[0006] According to the method for synthesizing noradrenaline hydrochloride of the above embodiment of the present invention, chloroacetylcatechol, a compound shown in Formula I, is used as a raw material to first prepare urotropine salt of chloroacetylcatechol, and then the urotropine salt of chloroacetylcatechol is hydrolyzed with hydrochloric acid to obtain noradrenaline hydrochloride. The method has the advantages of safe and simple operation, fast reaction speed, complete reaction of raw materials, and high product yield.
[0007] In addition, the synthesis method of noradrenaline hydrochloride according to the above embodiment of the present invention may also have the following additional technical features:
[0008] In some embodiments of the present invention, the molar ratio of the compound represented by formula I to the urotropine is 1:(1-3).
[0009] In some embodiments of the present invention, the first reaction is carried out in the presence of a catalyst and a first solvent.
[0010] In some embodiments of the present invention, the catalyst is selected from at least one of potassium iodide, sodium carbonate, and potassium carbonate.
[0011] In some embodiments of the present invention, the molar ratio of the compound represented by formula I to the catalyst is 1:(0.8-1.5).
[0012] In some embodiments of the present invention, the first solvent is selected from at least one of methanol, ethanol, and chlorobenzene.
[0013] In some embodiments of the present invention, the first reaction is carried out at 45-60° C. for 1-6 hours.
[0014] In some embodiments of the present invention, after the first reaction is completed, the method further comprises: cooling the reaction product to precipitate the compound represented by formula II.
[0015] In some embodiments of the present invention, the second reaction is performed in the presence of a second solvent.
[0016] In some embodiments of the present invention, the second solvent is selected from at least one of ethanol and water.
[0017] In some embodiments of the present invention, the second reaction is carried out at 20-50° C. for 1-3 h.
[0018] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. DETAILED DESCRIPTION
[0019] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention. If no specific techniques or conditions are specified in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used that do not specify the manufacturer are all conventional products that can be obtained commercially.
[0020] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include at least one of the features. In the description of the present invention, the meaning of "plurality" is at least two, such as two, three, etc., unless otherwise clearly and specifically defined.
[0021] In one aspect of the present invention, the present invention provides a method for synthesizing noradrenaline hydrochloride. The method for synthesizing noradrenaline hydrochloride according to an embodiment of the present invention is further described in detail below.
[0022] First, according to an embodiment of the present invention, a compound represented by formula I is reacted with urotropine to obtain a compound represented by formula II.
[0023]
[0024] According to some embodiments of the present invention, the molar ratio of the compound shown in Formula I to urotropine can be 1: (1-3), that is, relative to the amount of the compound shown in Formula I, the amount of urotropine can be 1eq-3eq, for example, 1eq, 1.1eq, 1.57eq, 2eq, 2.5eq, 3eq, etc. The inventors have found that if the amount of urotropine is too little, the reaction may not be complete and the yield may be reduced; if the amount of urotropine is too much, it may cause difficulties in post-processing and increase costs.
[0025] According to some embodiments of the present invention, the first reaction is performed in the presence of a catalyst and a first solvent.
[0026] According to some embodiments of the present invention, the catalyst is selected from at least one of potassium iodide, sodium carbonate, and potassium carbonate.
[0027] According to some embodiments of the present invention, the molar ratio of the compound shown in Formula I to the catalyst can be 1: (0.01-1.5), that is, relative to the amount of the compound shown in Formula I, the amount of the catalyst can be 0.8eq-1.5eq, for example, 0.8eq, 0.85eq, 1eq, 1.1eq, 1.2eq, 1.3eq, 1.5eq, etc., preferably 0.85eq-1.1eq. The inventors found that if the amount of the catalyst is too little, the reaction may not be complete, and more raw materials may remain; if the amount of the catalyst is too much, post-processing may be difficult and impurities may increase.
[0028] According to some embodiments of the present invention, the first solvent may be selected from at least one of methanol, ethanol, and chlorobenzene.
[0029] Preferably, according to some embodiments of the present invention, when potassium iodide is used as a catalyst, the first solvent is preferably methanol; when sodium carbonate is used as a catalyst, the first solvent is preferably ethanol. Potassium iodide has a certain solubility in methanol and is almost insoluble in ethanol, so methanol is preferably used as a solvent for potassium iodide catalytic reaction. When sodium carbonate is used as a catalyst, considering that methanol is a Class II solvent, ethanol is used as a solvent for green chemistry considerations.
[0030] According to some embodiments of the present invention, the first reaction can be carried out at 45 to 60°C for 1 to 6 hours. Specifically, the reaction temperature can be 45°C, 50°C, 55°C, 60°C, etc., and the reaction time can be 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, etc. The inventors have found that if the first reaction temperature is too low or the reaction time is too short, the reaction may be incomplete and more raw materials may remain; if the first reaction temperature is too high or the reaction time is too long, the impurity content may increase.
[0031] According to some embodiments of the present invention, after the first reaction is completed, the process further comprises: cooling the reaction product to precipitate the compound represented by formula II, and separating the compound represented by formula II by suction filtration.
[0032] Further, according to an embodiment of the present invention, the compound represented by formula II is mixed with hydrochloric acid and subjected to a second reaction to obtain the compound represented by formula III, noradrenaline hydrochloride.
[0033]
[0034] According to some embodiments of the present invention, the second reaction is performed in the presence of a second solvent.
[0035] According to some embodiments of the present invention, the second solvent may be selected from at least one of ethanol and water, and preferably is a mixed solvent of ethanol and water.
[0036] According to some embodiments of the present invention, the second reaction can be carried out at 20 to 50°C for 1 to 3 hours. Specifically, the reaction temperature can be 20°C, 30°C, 40°C, 50°C, etc., and the reaction time can be 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, etc. The inventors have found that if the second reaction temperature is too low or the reaction time is too short, the reaction may not be complete, too much hexamethylenetetramine residue may be left, and post-processing is difficult; if the second reaction temperature is too high or the reaction time is too long, side reactions may occur and the impurity content may increase.
[0037] The present invention is described below with reference to specific embodiments. It should be noted that these embodiments are merely illustrative and do not limit the present invention in any way.
[0038] Example 1
[0039] (1) In a 250 mL three-necked flask, 10.0 g of chloroacetylcatechol, 7.1 g (0.8 eq) of potassium iodide, and 60 mL of methanol were added, the temperature was raised to 50° C., and the mixture was stirred for 2 h.
[0040] (2) Dissolve 10.9 g of urotropine (1.45 eq) in 120 mL of methanol, add the mixture from step (1), and react for 3 h. After TLC detection, no residue of the raw material was found. The mixture was cooled and filtered to obtain the intermediate urotropine salt of chloroacetylcatechol.
[0041] (3) Take 10 g of the intermediate obtained in step (2), add 50 mL of ethanol, 10 mL of purified water, and 35.0 g of concentrated hydrochloric acid, hydrolyze at 30° C. for 3 h, and filter to obtain noradrenaline hydrochloride with a yield of 91.84%.
[0042] Example 2
[0043] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 1, except that in step (1), the amount of potassium iodide added was 0.85 eq; in step (2), the amount of urotropine added was 1 eq; the product yield was 50.4% and the purity was 99.5% (unless otherwise specified, the product purity was obtained by detection at a wavelength of 195 nm using a liquid chromatography ultraviolet detector).
[0044] Example 3
[0045] Noradrenaline hydrochloride was prepared in a method substantially the same as in Example 1, except that in step (1), the amount of potassium iodide added was 0.85 eq; in step (2), the amount of hexamethylenetetramine added was 1.1 eq; the product yield was 57.3% and the purity was 99.7%.
[0046] Example 4
[0047] Noradrenaline hydrochloride was prepared in a method substantially the same as in Example 1, except that in step (1), the amount of potassium iodide added was 0.85 eq; in step (2), the amount of hexamethylenetetramine added was 1.57 eq; the product yield was 61.5% and the purity was 99.4%.
[0048] Example 5
[0049] Noradrenaline hydrochloride was prepared in a method substantially the same as in Example 1, except that in step (1), the amount of potassium iodide added was 0.85 eq; in step (2), the amount of hexamethylenetetramine added was 2 eq; the product yield was 67.27% and the purity was 99.6%.
[0050] Example 6
[0051] Noradrenaline hydrochloride was prepared in a method substantially the same as in Example 1, except that in step (1), the amount of potassium iodide added was 0.85 eq; in step (2), the amount of hexamethylenetetramine added was 2.5 eq; the product yield was 66.4% and the purity was 99.3%.
[0052] Example 7
[0053] Noradrenaline hydrochloride was prepared in a method substantially the same as in Example 1, except that in step (1), the amount of potassium iodide added was 0.85 eq; in step (2), the amount of hexamethylenetetramine added was 3 eq; the product yield was 65.8% and the purity was 100%.
[0054] Example 8
[0055] (1) In a 250 mL three-necked flask, 10.0 g of chloroacetylcatechol, 8.9 g (1 eq) of potassium iodide, and 60 mL of methanol were added, the temperature was raised to 50°C, and the mixture was stirred for reaction for 3 h.
[0056] (2) Dissolve 15 g of urotropine (2 eq) in 120 mL of methanol, add the mixture from step (1), and react for 3 h. After TLC detection, no residue of the raw material is detected. Cool and filter to obtain the intermediate urotropine salt of chloroacetylcatechol.
[0057] (3) Take 10 g of the intermediate obtained in step (2), add 50 mL of ethanol, 10 mL of purified water, and 35.0 g of concentrated hydrochloric acid, hydrolyze at 30° C. for 3 h, and filter to obtain noradrenaline hydrochloride with a yield of 88.6% and a purity of 99.2%.
[0058] Example 9
[0059] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 8, except that in step (1), the amount of potassium iodide added was 1.1 eq; the product yield was 87.5% and the purity was 99.1%.
[0060] Example 10
[0061] Noradrenaline hydrochloride was prepared in a method substantially the same as in Example 8, except that in step (1), the amount of potassium iodide added was 1.5 eq; the product yield was 85.6% and the purity was 98.4%.
[0062] Embodiment 11
[0063] (1) In a 250 mL three-necked flask, 10.0 g of chloroacetylcatechol, 7.56 g (0.85 eq) of potassium iodide, and 60 mL of methanol were added, the temperature was raised to 50° C., and the mixture was stirred for reaction for 3 h.
[0064] (2) Dissolve 15 g of urotropine (2 eq) in 120 mL of methanol, add the mixture from step (1), and react for 3 h. After TLC detection, no residue of the raw material is detected. Cool and filter to obtain the intermediate urotropine salt of chloroacetylcatechol.
[0065] (3) Take 10 g of the intermediate obtained in step (2), add 50 mL of ethanol, 10 mL of purified water, and 35.0 g of concentrated hydrochloric acid, hydrolyze at 30° C. for 3 h, and filter to obtain noradrenaline hydrochloride with a yield of 91.84% and a purity of 100%.
[0066] Example 12
[0067] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (1), the catalyst was replaced by potassium carbonate and the solvent was replaced by ethanol; the product yield was 90.2% and the purity was 99.5%.
[0068] Embodiment 13
[0069] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (1), the solvent was replaced with chlorobenzene; the product yield was 91.7% and the purity was 100%.
[0070] Embodiment 14
[0071] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (1), the temperature was raised to 45° C.; the product yield was 88.4% and the purity was 98.4%.
[0072] Embodiment 15
[0073] Noradrenaline hydrochloride was prepared in the same manner as in Example 11. The yield of the product was 92.4% and the purity was 100%.
[0074] Example 16
[0075] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (1), the temperature was raised to 55° C.; the product yield was 89.2% and the purity was 99.2%.
[0076] Embodiment 17
[0077] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (1), the temperature was raised to 60° C.; the product yield was 88.6% and the purity was 98.1%.
[0078] Embodiment 18
[0079] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (3), hydrolysis was carried out at 20° C. for 3 h; the product yield was 89.3% and the purity was 99.7%.
[0080] Embodiment 19
[0081] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (3), hydrolysis was carried out at 40° C. for 3 h; the product yield was 89.1% and the purity was 100%.
[0082] Embodiment 20
[0083] Noradrenaline hydrochloride was prepared in a manner substantially similar to that of Example 11, except that in step (3), hydrolysis was carried out at 50° C. for 3 h. The product yield was 88.5% and the purity was 99.6%.
[0084] Embodiment 21
[0085] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (3), the amount of concentrated brine used was 20.0 g; the product yield was 93.1% and the purity was 100%.
[0086] Embodiment 22
[0087] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (3), the amount of concentrated brine used was 24.0 g; the product yield was 93.3% and the purity was 100%.
[0088] Embodiment 23
[0089] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (3), the amount of concentrated brine used was 28.0 g; the product yield was 92.45% and the purity was 99.8%.
[0090] Embodiment 24
[0091] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (3), the amount of concentrated brine used was 32.0 g; the product yield was 92.85% and the purity was 100%.
[0092] Embodiment 25
[0093] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that in step (3), the amount of concentrated brine used was 51.0 g; the product yield was 36.84% and the purity was 99.6%.
[0094] Embodiment 26
[0095] (1) In a 250 mL three-necked flask, 10.0 g of chloroacetylcatechol, 4.8 g (0.85 eq) of sodium carbonate, and 60 mL of ethanol were added, the temperature was raised to 55° C., and the mixture was stirred.
[0096] (2) Dissolve 16.35 g of urotropine (2.18 eq) in 120 mL of methanol, add the mixture from step (1), and react for 3 h. After TLC detection, no residue of the raw material was found. The mixture was cooled and filtered to obtain the intermediate urotropine salt of chloroacetylcatechol.
[0097] (3) Take 10 g of the intermediate obtained in step (2), add 50 mL of ethanol, 10 mL of purified water, and 35.0 g of concentrated hydrochloric acid, hydrolyze at 30° C. for 2 h, and filter to obtain noradrenaline hydrochloride with a yield of 90.3%.
[0098] Embodiment 27
[0099] Noradrenaline hydrochloride was prepared in a method substantially the same as that in Example 1, except that the amount of urotropine added in step (2) was 3 eq, and the yield of the product noradrenaline hydrochloride was 65.8%.
[0100] Embodiment 28
[0101] Noradrenaline hydrochloride was prepared in a method substantially the same as that in Example 2, except that the amount of sodium carbonate added in step (1) was 1.2 eq, and the yield of the product noradrenaline hydrochloride was 87.5%.
[0102] Comparative Example 1
[0103] Noradrenaline hydrochloride was prepared in a method substantially the same as that in Example 2, except that the amount of urotropine added in step (2) was 0.5 eq, and the yield of the product noradrenaline hydrochloride was 34.7%.
[0104] In this comparative example, the amount of hexamethylenetetramine added was too low, resulting in incomplete reaction and reduced yield.
[0105] Comparative Example 2
[0106] Noradrenaline hydrochloride was prepared in a method substantially the same as that in Example 2, except that the temperature of the reaction system was controlled to be 40° C. in step (1), and the reaction was continued for 0.5 h after the addition of urotropine in step (2). The yield of the product noradrenaline hydrochloride was 40.6%.
[0107] In this comparative example, the reaction temperature in the step of synthesizing the urotropine salt of chloroacetylcatechol was too low and the reaction time was too short, resulting in incomplete reaction and a large amount of raw material residue.
[0108] Comparative Example 3
[0109] Noradrenaline hydrochloride was prepared in a method substantially the same as that in Example 2, except that the temperature of the reaction system was controlled to be 70° C. in step (1), and the reaction was continued for 8 h after the addition of urotropine in step (2). The yield of the product noradrenaline hydrochloride was 50.6%.
[0110] In this comparative example, the reaction temperature in the step of synthesizing the urotropine salt of chloroacetylcatechol was too high and the reaction time was too long, resulting in an increase in the impurity content.
[0111] Comparative Example 4
[0112] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 8, except that the amount of potassium iodide added in step (1) was 0.01 eq. As a result, no product was obtained.
[0113] Comparative Example 5
[0114] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 8, except that the amount of potassium iodide added in step (1) was 0.05 eq. As a result, no product was obtained.
[0115] Comparative Example 6
[0116] Noradrenaline hydrochloride was prepared in a manner substantially the same as in Example 11, except that purified water was not added as a solvent in step (3); the product yield was 80.1% and the purity was 99.6%.
[0117] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0118] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A method for synthesizing noradrenaline hydrochloride, characterized in that: include: (1) subjecting the compound represented by formula I to a first reaction with urotropine to obtain a compound represented by formula II; The first reaction is carried out in the presence of a catalyst and a first solvent, wherein the catalyst is selected from at least one of potassium iodide, sodium carbonate and potassium carbonate; The first reaction is carried out at 45-55° C. for 1-6 hours; (2) mixing the compound represented by formula II with hydrochloric acid and performing a second reaction to obtain the compound represented by formula III, noradrenaline hydrochloride; the second reaction is performed at 20 to 50° C. for 1 to 3 hours; 2. The method for synthesizing noradrenaline hydrochloride according to claim 1, characterized in that: The molar ratio of the compound represented by formula I to the urotropine is 1:(1-3).
3. The method for synthesizing noradrenaline hydrochloride according to claim 1, characterized in that: The molar ratio of the compound represented by formula I to the catalyst is 1:(0.8-1.5).
4. The method for synthesizing noradrenaline hydrochloride according to claim 1, characterized in that: The first solvent is selected from at least one of methanol, ethanol and chlorobenzene.
5. The method for synthesizing noradrenaline hydrochloride according to claim 1, characterized in that: After the first reaction is completed, the method further comprises: cooling the reaction product to precipitate the compound represented by formula II.
6. The method for synthesizing noradrenaline hydrochloride according to claim 1, characterized in that: The second reaction is carried out in the presence of a second solvent.
7. The method for synthesizing noradrenaline hydrochloride according to claim 6, characterized in that: The second solvent is selected from at least one of ethanol and water.
Citation Information
Patent Citations
Preparation method of norepinephrine
CN107298646A
